The primary goal of the Administrative Services Core will be to provide the integration, administrative support and oversight necessary for the projects and cores to accomplish the overall specific aims of the Immunotherapeutics of Ovarian Cancer P01 as outlined by corresponding the 4 projects. The Administrative Core will be led by Dr. Spriggs.
The specific aims are: 1) To create synergy among the 4 projects and the cores; 2) To provide seamless budgetary oversight for the programs and cores; 3) To schedule and support the program meetings, as well as facilitate evaluation and communications among the projects; 4) To distribute and archive the publications, reports and grant elements from the components of the PO1; 5) To schedule, facilitate and manage the meetings of the executive committee, the internal advisory committee and the external advisory committee.
The primary goal of the Administrative Services Core will be to provide the administrative support and oversight necessary for the projects and cores to accomplish the overall specific aims of the Immunotherapeutics of Ovarian Cancer P01 as outlined by corresponding the 4 projects. The Administrative Core will be led by Dr. Spriggs. The specific aims are: 1) To insure synergy among the 4 projects and 3 cores; 2)To provide seamless budgetary oversight for the programs and cores; 3) To schedule and support the program meetings, as well as facilitate evaluation and communications among the projects; 4) To distribute and archive the publications, reports and grant elements from the components of the PO1; 5) To schedule, facilitate and manage the meetings of the executive committee, the internal advisory committee and the external advisory committee.
| Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141 |
| Knorr, David A; Dahan, Rony; Ravetch, Jeffrey V (2018) Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. Proc Natl Acad Sci U S A 115:11048-11053 |
| Cornetta, Kenneth; Duffy, Lisa; Feldman, Steven A et al. (2018) Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. Mol Ther Methods Clin Dev 10:371-378 |
| Rafiq, Sarwish; Yeku, Oladapo O; Jackson, Hollie J et al. (2018) Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36:847-856 |
| Bournazos, Stylianos; Ravetch, Jeffrey V (2017) Fc? Receptor Function and the Design of Vaccination Strategies. Immunity 47:224-233 |
| Hectors, Stefanie J; Wagner, Mathilde; Bane, Octavia et al. (2017) Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Sci Rep 7:2452 |
| Yeku, Oladapo; Li, Xinghuo; Brentjens, Renier J (2017) Adoptive T-Cell Therapy for Solid Tumors. Am Soc Clin Oncol Educ Book 37:193-204 |
| Szender, J Brian; Papanicolau-Sengos, Antonios; Eng, Kevin H et al. (2017) NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 145:420-425 |
| Rao, Thapi Dharma; Fernández-Tejada, Alberto; Axelrod, Abram et al. (2017) Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. ACS Chem Biol 12:2085-2096 |
| Bournazos, Stylianos; Wang, Taia T; Dahan, Rony et al. (2017) Signaling by Antibodies: Recent Progress. Annu Rev Immunol 35:285-311 |
Showing the most recent 10 out of 22 publications
